Duchesnay Drug Patent Portfolio
Duchesnay owns 3 orange book drugs protected by 14 US patents Given below is the list of Duchesnay's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9089489 | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof | 18 Feb, 2033 | Active |
| US9375404 | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof | 18 Feb, 2033 | Active |
| US9526703 | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof | 18 Feb, 2033 | Active |
| US9937132 | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof | 18 Feb, 2033 | Active |
| US8642079 | Solid formulations of ospemifene | 09 Jul, 2028 | Active |
| US8236861 | Method for enhancing the bioavailablity of ospemifene | 11 Aug, 2026 | Active |
| US6245819 | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause | 21 Jul, 2025 | Active |
| US8470890 | Method for enhancing the bioavailability of ospemifene | 13 Feb, 2024 | Expired |
| US8772353 | Method for enhancing the bioavalability of ospemifene | 13 Feb, 2024 | Expired |
| US9241915 | Method for enhancing the bioavailability of ospemifene | 13 Feb, 2024 | Expired |
| US9855224 | Method for enhancing the bioavailability of ospemifene | 13 Feb, 2024 | Expired |
| US9566252 | Method for the alleviation of dyspareunia in women | 02 Nov, 2022 | Expired |
| US6340695 | Rapid onset formulation | 21 Jun, 2021 | Expired |
| US7560122 | Pharmaceutical dosage form bearing pregnancy-friendly indicia | 25 Jan, 2019 | Expired |
Latest Legal Activities on Duchesnay's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Duchesnay.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Expire Patent
Critical
| 04 Mar, 2024 | US9241915 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 07 Feb, 2024 | US8236861 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 15 Jan, 2024 | US9526703 |
|
Maintenance Fee Reminder Mailed
Critical
| 18 Sep, 2023 | US9241915 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 26 Jul, 2023 | US9375404 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 12 Dec, 2022 | US9089489 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jan, 2022 | US8772353 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 29 Sep, 2021 | US9937132 |
|
Expire Patent
Critical
| 16 Aug, 2021 | US7560122 |
|
Expire Patent
Critical
| 16 Aug, 2021 | US7560122 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Jul, 2021 | US8642079 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Jun, 2021 | US9855224 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Mar, 2021 | US7560122 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Mar, 2021 | US7560122 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Oct, 2020 | US8470890 |
Duchesnay's Drug Patent Litigations
Duchesnay's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 19, 2013, against patent number US9566252. The petitioner , challenged the validity of this patent, with Kaija Halonen et al as the respondent. Click below to track the latest information on how companies are challenging Duchesnay's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9566252 | August, 2013 |
Decision
(06 Jul, 2016)
| Kaija Halonen et al | |
Duchesnay's Family Patents
Duchesnay Drug List
Given below is the complete list of Duchesnay's drugs and the patents protecting them.
1. Bonjesta
Bonjesta is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9089489 | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
18 Feb, 2033
(8 years from now)
| Active |
| US9375404 | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
18 Feb, 2033
(8 years from now)
| Active |
| US9526703 | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
18 Feb, 2033
(8 years from now)
| Active |
| US9937132 | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
18 Feb, 2033
(8 years from now)
| Active |
| US7560122 | Pharmaceutical dosage form bearing pregnancy-friendly indicia |
25 Jan, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bonjesta's drug page
2. Diclegis
Diclegis is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6340695 | Rapid onset formulation |
21 Jun, 2021
(3 years ago)
| Expired |
| US7560122 | Pharmaceutical dosage form bearing pregnancy-friendly indicia |
25 Jan, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Diclegis's drug page
3. Osphena
Osphena is protected by 8 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8642079 | Solid formulations of ospemifene |
09 Jul, 2028
(3 years from now)
| Active |
| US8236861 | Method for enhancing the bioavailablity of ospemifene |
11 Aug, 2026
(1 year, 7 months from now)
| Active |
| US6245819 | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
21 Jul, 2025
(7 months from now)
| Active |
| US8470890 | Method for enhancing the bioavailability of ospemifene |
13 Feb, 2024
(10 months ago)
| Expired |
| US8772353 | Method for enhancing the bioavalability of ospemifene |
13 Feb, 2024
(10 months ago)
| Expired |
| US9241915 | Method for enhancing the bioavailability of ospemifene |
13 Feb, 2024
(10 months ago)
| Expired |
| US9855224 | Method for enhancing the bioavailability of ospemifene |
13 Feb, 2024
(10 months ago)
| Expired |
| US9566252 | Method for the alleviation of dyspareunia in women |
02 Nov, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Osphena's drug page